ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical (CLSD), Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

– The vast majority of patients on the “go-forward” regimen had no inflammation and >90% of patients have no or minimal inflammation (0 or 0.5+ AC cells) – – Preliminary efficacy and safety data ...

People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...

If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

Resveratrol supplementation in wet AMD patients led to fewer aflibercept injections and reduced macular fibrosis progression over two years. Both treatment groups showed significant improvements in ...

When ophthalmologist Richard B. Rosen, MD, of New York Eye and Ear Infirmary of Mount Sinai in New York City, started his career more than 30 years ago, advanced age-related macular degeneration (AMD) ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...